Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Long Term Safety and Efficacy Analysis (CA180-188) [ROLLOVER OF 700001390, 700001940, 700001399, 700001382, 700002010 and 700016294]

Trial Profile

Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Long Term Safety and Efficacy Analysis (CA180-188) [ROLLOVER OF 700001390, 700001940, 700001399, 700001382, 700002010 and 700016294]

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms START
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 28 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top